| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Ben Gree. Focus on aripiprazole. Current medical research and opinion. vol 20. issue 2. 2004-05-27. PMID:15006016. |
aripiprazole is an antipsychotic drug with high affinity for d(2)- and d(3)-receptors and the dopamine autoreceptor. |
2004-05-27 |
2023-08-12 |
Not clear |
| Jeffrey A Lieberma. Dopamine partial agonists: a new class of antipsychotic. CNS drugs. vol 18. issue 4. 2004-05-10. PMID:15015905. |
in conclusion, the findings from clinical studies of aripiprazole show that dopamine partial agonists offer a novel, effective and well-tolerated treatment approach for patients with schizophrenia. |
2004-05-10 |
2023-08-12 |
Not clear |
| Satoru Nakai, Tsuyoshi Hirose, Yasufumi Uwahodo, Takeshi Imaoka, Hiroshi Okazaki, Takashi Miwa, Masami Nakai, Sakiko Yamada, Bob Dunn, Kevin D Burris, Perry B Molinoff, Katsura Tottori, C Anthony Altar, Tetsuro Kikuch. Diminished catalepsy and dopamine metabolism distinguish aripiprazole from haloperidol or risperidone. European journal of pharmacology. vol 472. issue 1-2. 2004-04-23. PMID:12860477. |
diminished catalepsy and dopamine metabolism distinguish aripiprazole from haloperidol or risperidone. |
2004-04-23 |
2023-08-12 |
mouse |
| Satoru Nakai, Tsuyoshi Hirose, Yasufumi Uwahodo, Takeshi Imaoka, Hiroshi Okazaki, Takashi Miwa, Masami Nakai, Sakiko Yamada, Bob Dunn, Kevin D Burris, Perry B Molinoff, Katsura Tottori, C Anthony Altar, Tetsuro Kikuch. Diminished catalepsy and dopamine metabolism distinguish aripiprazole from haloperidol or risperidone. European journal of pharmacology. vol 472. issue 1-2. 2004-04-23. PMID:12860477. |
catalepsy and changes in striatal and limbic dopamine metabolism were investigated in mice after oral administration of aripiprazole, haloperidol, and risperidone. |
2004-04-23 |
2023-08-12 |
mouse |
| Satoru Nakai, Tsuyoshi Hirose, Yasufumi Uwahodo, Takeshi Imaoka, Hiroshi Okazaki, Takashi Miwa, Masami Nakai, Sakiko Yamada, Bob Dunn, Kevin D Burris, Perry B Molinoff, Katsura Tottori, C Anthony Altar, Tetsuro Kikuch. Diminished catalepsy and dopamine metabolism distinguish aripiprazole from haloperidol or risperidone. European journal of pharmacology. vol 472. issue 1-2. 2004-04-23. PMID:12860477. |
at the time of maximal catalepsy, acute aripiprazole did not alter neostriatal dopamine metabolite/dopamine ratios or homovanillic acid (hva) levels, and produced small increases in dihydroxyphenylacetic acid (dopac). |
2004-04-23 |
2023-08-12 |
mouse |
| Satoru Nakai, Tsuyoshi Hirose, Yasufumi Uwahodo, Takeshi Imaoka, Hiroshi Okazaki, Takashi Miwa, Masami Nakai, Sakiko Yamada, Bob Dunn, Kevin D Burris, Perry B Molinoff, Katsura Tottori, C Anthony Altar, Tetsuro Kikuch. Diminished catalepsy and dopamine metabolism distinguish aripiprazole from haloperidol or risperidone. European journal of pharmacology. vol 472. issue 1-2. 2004-04-23. PMID:12860477. |
dopamine metabolism was essentially unchanged in both regions after chronic aripiprazole. |
2004-04-23 |
2023-08-12 |
mouse |
| Satoru Nakai, Tsuyoshi Hirose, Yasufumi Uwahodo, Takeshi Imaoka, Hiroshi Okazaki, Takashi Miwa, Masami Nakai, Sakiko Yamada, Bob Dunn, Kevin D Burris, Perry B Molinoff, Katsura Tottori, C Anthony Altar, Tetsuro Kikuch. Diminished catalepsy and dopamine metabolism distinguish aripiprazole from haloperidol or risperidone. European journal of pharmacology. vol 472. issue 1-2. 2004-04-23. PMID:12860477. |
the subtle effects of aripiprazole on striatal and limbic dopamine metabolism, and the decrease in catalepsy with chronic administration, illustrate fundamental differences in dopamine neurochemical actions and behavioral sequelae of aripiprazole compared to haloperidol or risperidone. |
2004-04-23 |
2023-08-12 |
mouse |
| John R DeQuard. Worsened agitation with aripiprazole: adverse effect of dopamine partial agonism? The Journal of clinical psychiatry. vol 65. issue 1. 2004-03-02. PMID:14976671. |
worsened agitation with aripiprazole: adverse effect of dopamine partial agonism? |
2004-03-02 |
2023-08-12 |
Not clear |
| Gerhard Grunder, Arvid Carlsson, Dean F Won. Mechanism of new antipsychotic medications: occupancy is not just antagonism. Archives of general psychiatry. vol 60. issue 10. 2004-01-12. PMID:14557141. |
however, the novel atypical antipsychotic drug, aripiprazole, occupies up to 95% of striatal d2-like dopamine receptors at clinical doses, and the incidence of extrapyramidal side effects with aripiprazole is no higher than with placebo. |
2004-01-12 |
2023-08-12 |
Not clear |
| Gerhard Grunder, Arvid Carlsson, Dean F Won. Mechanism of new antipsychotic medications: occupancy is not just antagonism. Archives of general psychiatry. vol 60. issue 10. 2004-01-12. PMID:14557141. |
the most likely explanation for this finding is aripiprazole's weak partial agonism at d2-like dopamine receptors. |
2004-01-12 |
2023-08-12 |
Not clear |
| G Gründer, D F Won. [The next generation of "atypical" antipsychotics: the role of positron emission tomography]. Fortschritte der Neurologie-Psychiatrie. vol 71. issue 8. 2003-10-15. PMID:12910447. |
aripiprazole, of which the antipsychotic efficacy has been proven in various multicenter clinical trials, leads to almost complete saturation of d2 -like dopamine receptors at clinically used doses; however, the incidence of extrapyramidal side effects under aripiprazole is not higher than under placebo. |
2003-10-15 |
2023-08-12 |
Not clear |
| Steven G Potkin, Anutosh R Saha, Mary J Kujawa, William H Carson, Mirza Ali, Elyse Stock, Joseph Stringfellow, Gary Ingenito, Stephen R Marde. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Archives of general psychiatry. vol 60. issue 7. 2003-09-16. PMID:12860772. |
aripiprazole is a dopamine d2 receptor partial agonist with partial agonist activity at serotonin 5ht1a receptors and antagonist activity at 5ht2a receptors. |
2003-09-16 |
2023-08-12 |
Not clear |
| Peter F Buckle. Aripiprazole: efficacy and tolerability profile of a novel-acting atypical antipsychotic. Drugs of today (Barcelona, Spain : 1998). vol 39. issue 2. 2003-09-04. PMID:12698209. |
aripiprazole, the latest atypical antipsychotic to come to clinical practice, has a proposed mechanism of action different to other agents, most notably in its partial agonist action at dopamine (d2) receptors and at serotonin (5ht1a) receptors. |
2003-09-04 |
2023-08-12 |
Not clear |
| Hans O Kalkman, Erika Loetsche. alpha2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs. European journal of pharmacology. vol 462. issue 1-3. 2003-07-02. PMID:12591093. |
therefore, the antagonistic potencies of the antipsychotics clozapine, chlorpromazine, risperidone, olanzapine, haloperidol, quetiapine, ziprasidone, iloperidone and aripiprazole were quantified using cell lines expressing the recombinant human alpha(2c)-adrenoceptor, alpha(2a)-adrenoceptor, or dopamine d(2l) receptor. |
2003-07-02 |
2023-08-12 |
human |
| Paul E Keck, Susan L McElro. Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic. Expert opinion on investigational drugs. vol 12. issue 4. 2003-06-10. PMID:12665420. |
aripiprazole: a partial dopamine d2 receptor agonist antipsychotic. |
2003-06-10 |
2023-08-12 |
Not clear |
| Paul E Keck, Susan L McElro. Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic. Expert opinion on investigational drugs. vol 12. issue 4. 2003-06-10. PMID:12665420. |
aripiprazole has a unique mechanism of action as a dopamine d2 partial agonist, serotonin 5-ht(1a) partial agonist and serotonin 5-ht(2a) antagonist. |
2003-06-10 |
2023-08-12 |
Not clear |
| Paul J Goodnick, Jason M Jerr. Aripiprazole: profile on efficacy and safety. Expert opinion on pharmacotherapy. vol 3. issue 12. 2003-05-05. PMID:12472374. |
aripiprazole exhibits typical antagonism at dopamine (d2) receptors in the mesolimbic pathway, as well as having unique partial agonist activity at d2 receptors in the mesocortical pathway. |
2003-05-05 |
2023-08-12 |
Not clear |
| Shaun Jordan, Vuk Koprivica, Ruoyan Chen, Katsura Tottori, Tetsuro Kikuchi, C Anthony Alta. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. European journal of pharmacology. vol 441. issue 3. 2002-12-31. PMID:12063084. |
aripiprazole, 7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy]-3,4-dihydro-2(1h)-quinolinone, a novel antipsychotic with partial agonist activity at dopamine d2 receptors, bound with high affinity to recombinant human 5-ht(1a) receptors (h5-ht(1a)) in chinese hamster ovary cell membranes and displayed potent, partial agonism at 5-ht(1a) receptors in a guanosine-5'-o-(3-[(35)s]thio)-triphosphate ([(35)s]gtp gamma s)-binding assay that was blocked completely by a selective 5-ht(1a) receptor antagonist. |
2002-12-31 |
2023-08-12 |
human |
| Shaun Jordan, Vuk Koprivica, Ruoyan Chen, Katsura Tottori, Tetsuro Kikuchi, C Anthony Alta. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. European journal of pharmacology. vol 441. issue 3. 2002-12-31. PMID:12063084. |
combined with previous studies demonstrating the potent partial agonism of aripiprazole at dopamine d2 receptors, this study suggests aripiprazole is the first dopamine-serotonin system stabilizer. |
2002-12-31 |
2023-08-12 |
human |
| Vural Ozdemir, Jeanne Fourie, Fatih Ozdene. Aripiprazole (Otsuka Pharmaceutical Co). Current opinion in investigational drugs (London, England : 2000). vol 3. issue 1. 2002-12-17. PMID:12054061. |
otsuka pharmaceuticals in collaboration with bristol-myers squibb is developing aripiprazole, a dual dopamine autoreceptor agonist and postsynaptic d2 receptor antagonist, for the potential treatment of psychoses including schizophrenia [281327], [340364]. |
2002-12-17 |
2023-08-12 |
Not clear |